Jeffrey Alan Jones is Chief Medical Officer at Cullinan Therapeutics, Inc. (CGEM). They have made 13 open-market trades across 2 companies since 2020, most recently 2026-02-24.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $194K since 2020, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 159,968 | $2.1M |
| WSR | 39,478 | $750K |
| Total | $2.8M |
Shares reported on the most recent Form 4, priced at the 2026-02-25 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL | 2026-02-24 | 2026-02-25 | $14.47 | $66K | +6.8% | -10.4% | +7.9% |
| CGEM | SELL | 2026-02-20 | 2026-02-23 | $13.62 | $68K | +11.1% | +0.0% | +10.1% |
| CGEM | SELL | 2025-12-18 | 2025-12-19 | $9.67 | $45K | +2.4% | +10.0% | +32.5% |
| CGEM | SELL | 2025-02-25 | 2025-02-27 | $8.53 | $42K | +0.2% | -12.5% | -9.4% |
| CGEM | SELL | 2024-12-18 | 2024-12-20 | $11.41 | $106K | +9.2% | -10.2% | -24.9% |
| CGEM | SELL | 2023-12-21 | 2023-12-22 | $8.50 | $16K | +10.1% | +34.3% | +76.8% |
| CGEM | SELL | 2023-12-18 | 2023-12-20 | $8.22 | $3K | +22.6% | +35.6% | +82.6% |
| CGEM | SELL | 2023-06-20 | 2023-06-21 | $12.94 | $5K | -16.7% | -18.5% | -20.3% |
| CGEM | SELL | 2023-05-18 | 2023-05-19 | $8.76 | $3K | +12.0% | +44.1% | +11.1% |
| CGEM | SELL | 2023-04-18 | 2023-04-20 | $10.71 | $4K | -6.3% | -12.3% | +7.0% |
| CGEM | SELL | 2023-03-20 | 2023-03-27 | $11.32 | $4K | -7.6% | -7.9% | +4.5% |
| WSR | BUY | 2021-03-22 | 2022-04-01 | $9.55 | $119K | -2.2% | -10.4% | -19.2% |
| WSR | BUY | 2020-02-28 | 2020-03-02 | $12.00 | $75K | -31.1% | -54.4% | -50.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.